COmprehensive Unbiased Risk factor Assessment for Genetics and Environment in Parkinson‘s Disease

SCHEME: INTER

CALL: 2013

DOMAIN: BM - Life Sciences, Biology and Medicine

FIRST NAME: Rudi

LAST NAME: Balling

INDUSTRY PARTNERSHIP / PPP: No

INDUSTRY / PPP PARTNER:

HOST INSTITUTION: University of Luxembourg

KEYWORDS: Parkinson’s disease, genetics, next generation sequencing, environmental exposures, Mendelian randomization, induced pluripotent stem cells, mitochondrial dysfunction, protein aggregation

START: 2014-03-01

END: 2017-02-28

WEBSITE: https://www.uni.lu

Submitted Abstract

Despite the advances in the identification of genes involved in Parkinson’s disease (PD), there are still appreciable gaps in our understanding of the mechanisms underlying the neurodegenerative process and its relation to environmental factors in PD. Therefore we are proposing a comprehensive approach based on (i) a unique collection of families with autosomal dominant and autosomal recessive PD and (ii) large cohorts of clinically well-defined sporadic PD patients from different populations worldwide for (iii) genetic studies and (iv) assessment of environmental modifiers that will translate into (v) functional validation studies in patient-derived cellular models. Using next generation sequencing strategies including exome sequencing in multiplex families and targeted resequencing in sporadic PD patients, we will disentangle the complex genetic architecture of PD in different populations and attempt to better define the underlying functional variants in disease-associated GWAS loci. Newly identified genetic variants are filtered for pathogenic relevance based on novel prediction algorithms combined with unique expression databases and replicated in large cohorts of PD patients. Here the Genetic Epidemiology of Parkinson’s disease Consortium (GEO-PD) provides a unique resource with a large number of DNA samples and environmental exposure data of PD patients and controls from different populations worldwide. Subsequent assessment of disease modifiers includes two complementary approaches: Mendelian randomization, and gene-environment interaction studies. In order to validate genetic risk variants, functional studies on patient-based material will be performed. Here the applicants provide unique expertise for fibroblasts- and induced-pluripotent-stem-cells-(iPSC)-derived cellular models of PD and a large repository of biomaterials from carriers of PD-associated mutations. Established readouts allow to study functional effects of identified genetic risk factors and will be used to assign novel disease genes and risk variants to defined pathogenic pathways. Moreover patient-based cellular models will be challenged with environmental risk factors identified as modulators of disease. We expect that the combination of comprehensive state-of-the-art genetic technologies with a detailed ascertainment of environmental modifiers will provide important clues to decipher the complexity of neurodegeneration in PD. Subsequent modelling of PD in patient-based material allows to discover molecular mechanisms and pathways involved and leading to therapies for this still incurable disease. •Brief assessment of the projects relevance for the aims of the call COURAGE-PD projects provides a novel and comprehensive large-scale genetico-epidemiological approach including functional validation studies based on stem-cell-technology to dissect the complex architecture of PD as the most common neurodegenerative movement disorders. To comply with the important challenges that heterogeneous neurodegenerative diseases like PD impose to the ageing societies worldwide, our ambitious and innovative approach integrates unique resources from the GEO-PD Consortium and MEFOPA-Consortium that provide one of the largest repositories for DNA, exposure data and biomaterial of PD patients and controls. Based on state-of-the-art genotyping technologies we will identify novel monogenic causes and functional variants in previously defined GWAS loci that contribute to the common sporadic form of PD. Combining advanced biostatistical analyses with expression databases including regional methylation patterns to assess epigenetic regulation, we are able to filter genetic data from our screening approach and validate in large cohorts of well-characterized PD patients from populations worldwide based on COURAGE-GEO-PD Chip.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement